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Background: NLRP3 is a key regulator of innate inflammation and is linked to inflammatory diseases.
Results: GPSM3 associates with NLRP3 and inhibits its function.
Conclusion: GPSM3 specifically inhibits NLRP3-dependent inflammasome activity by interacting with its leucine-rich repeat
domain.
Significance: This association uncovers a putative new mechanism of NLRP3 control, linking a G protein modulator to
NLRP3-dependent inflammatory diseases.
Inflammasomes are multi-protein complexes that regulate
maturation of the interleukin 1-related cytokines IL-1 and
IL-18 through activation of the cysteine proteinase caspase-1.
NOD-like receptor family, pyrin domain containing 3 (NLRP3)
protein is a key component of inflammasomes that assemble in
response to a wide variety of endogenous and pathogen-derived
danger signals. Activation of the NLRP3-inflammasome and
subsequent secretion of IL-1 is highly regulated by at least
three processes: transcriptional activation of both NLRP3 and
pro-IL-1 genes, non-transcriptional priming of NLRP3, and
final activation of NLRP3. NLRP3 is predominantly expressed in
cells of the hematopoietic lineage. Using a yeast two-hybrid
screen, we identified the hematopoietic-restricted protein, G
protein signaling modulator-3 (GPSM3), as a NLRP3-inter-
acting protein and a negative regulator of IL-1 production
triggered by NLRP3-dependent inflammasome activators. In
monocytes, GPSM3 associates with the C-terminal leucine-rich
repeat domain of NLRP3. Bone marrow-derived macro-
phages lacking GPSM3 expression exhibit an increase in
NLRP3-dependent IL-1, but not TNF-, secretion. Further-
more, GPSM3-null mice have enhanced serum and peritoneal
IL-1 production following Alum-induced peritonitis. Our
findings suggest that GPSM3 acts as a direct negative regula-
tor of NLRP3 function.
Phagocytic mononuclear cells such as monocytes and
macrophages respond to host and environmental cues through
numerous signal transduction pathways to coordinate inflam-
matory responses. The release of IL-1 and IL-18 from these
cells plays a major role in inflammatory responses to challenge
with infectious agents and in aseptic inflammatory conditions
(1). These cytokines are produced as inactive cytoplasmic pro-
cytokines and require specialized proteolytic processing and
secretion mechanisms to be released as biologically active mol-
ecules. The proteolytic processing is carried out by a specific
cysteine proteinase, caspase-1 (2). Caspase-1 is synthesized as
an inactive pro-enzyme and activation of procaspase-1 is tightly
regulated (3). Multiprotein complexes known as inflammasomes
activate caspase-1 in response to numerous pro-inflammatory
stimuli (4). While all inflammasomes activate caspase-1, inflam-
masomes are assembled from various core protein components
each of which has a defined range of triggers.
Inflammasome activation of procaspase-1 is ultimately
responsible for proteolytic processing of the precursors of
IL-1 and IL-18 into mature, active cytokines (4). In addition to
procaspase-1, inflammasomes are known to contain other cel-
lular proteins, including the adapter proteins Apoptotic Speck
protein containing a Card (or ASC)3 and Cardinal (also known
as CARD8 or TUCAN), as well as a NOD-like receptor (NLR)
protein family member (4). The mammalian genome encodes
23 NLR gene family members, each defined by a conserved
tripartite protein structure of a variable number of leucine-rich
repeat at the C terminus, a central nucleotide-binding oligo-
merization domain, and an N-terminal effector domain. Most
NLR effector domains are either caspase activation and recruit-
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ment domains (CARD), leading to the designation NLRC, or
pyrin domains, leading to the designation NLRP (5). The
immunologic signaling pathways within which many of these
NLR proteins participate have been elucidated both through
genetic disease associations and through cell biological and bio-
chemical analyses of their function (6).
Of all inflammasome-forming proteins, NLRP3 is acti-
vated by the broadest range of stimuli and has been
implicated in the pathogenesis of a wide array of autoinflam-
matory conditions, sterile inflammatory conditions, and infec-
tious diseases. Monosodium urate and calcium pyrophosphate
crystals, underlying causes of the sterile inflammatory arthriti-
des gout and pseudogout, cause the activation of caspase-1 and
secretion of IL-1; macrophages from NLRP3-deficient mice
fail to secrete IL-1 in response to either stimuli (7). Addition-
ally, crystals linked to various other pathologic inflammatory
processes are known to signal through NLRP3, including asbes-
tos, silica, and -amyloid fibrils (8 –10). Aluminum hydroxide,
a vaccine adjuvant used in humans, also stimulates the release
of NLRP3-inflammasome-processed cytokines. NLRP3-defi-
cient mice have blunted immunologic responses to vaccina-
tions accompanied by aluminum hydroxide, suggesting that
NLRP3 plays an important role in the adaptive immune
response in this setting as well (10, 11). In addition, several
biochemical moieties produced by infectious disease agents or
host inflammatory processes, named pathogen-associated
molecular patterns (PAMPs) and damage-associated molecular
patterns (DAMPs), are known to activate the NLRP3-dependent
inflammasome; PAMPs and DAMPs include pore-forming toxins,
pathogen-related RNA and DNA species, host cell-derived ATP
and DNA, and hyaluronan generated from cellular damage (12).
Activation of the NLRP3 inflammasome in response to these
diverse stimuli is controlled by a series of transcriptional and post-
transcriptional mechanisms that include up-regulation of NLRP3
and involvement of the chaperonin HSP90 and the deubiquitinase
BRCC3 (13–15).
Some of us have recently described functional studies of G
protein signaling modulator-3 (GPSM3), a newly identified sig-
naling regulator with prominent expression in myeloid lineage
cells and lower relative expression levels in other hematopoietic
lineages as well as non-hematopoietic tissues (16). GPSM3
(a.k.a. AGS4 or G18; Ref. 17, 18) possesses two functional
“GoLoco motifs” (18) for binding heterotrimeric G protein Gi
subunits and additionally binds to G subunits during their
synthetic pathway toward forming mature G dimers (19);
these interactions with heterotrimeric G protein subunits are
thought to underlie the effects of GPSM3 on chemokine recep-
tor signaling that is critical to the development of inflammatory
arthritis (16). More recently, we have described GPSM3 as also
interacting directly with the adaptor protein 14-3-3 (20). To
identify additional interacting partner(s) that might be involved
in GPSM3-mediated signaling regulation, a yeast two-hybrid
screen was performed using full-length GPSM3 as bait. This
screen (19) identified one clone encoding a C-terminal frag-
ment of NLRP3. Based their co-expression in myeloid lineage
cells and the discovery of their potential association by yeast
two-hybrid screening, we investigated the role of GPSM3 in
NLRP3-mediated IL-1 production and further characterized
this association using biochemical approaches. Our data indi-
cate a modulatory function of GPSM3 on NLRP3-dependent
IL-1 generation.
MATERIALS AND METHODS
Commercial Antibodies, Constructs, and Other Reagents—
Horseradish peroxidase (HRP)-conjugated anti-hemagglutinin
(HA) monoclonal antibody (clone 3F10) was obtained from
Roche Diagnostics. Anti-Flag M2 antibody, and agarose-conju-
gated anti-Flag M2 antibody were purchased from Sigma. HRP-
conjugated goat anti-mouse and goat anti-rabbit antibodies
were from GE Healthcare (Piscataway, NJ). Anti-GFP Abfinity
antibody was from Invitrogen. Mouse monoclonal anti-NLRP3
clone cryo-2 was from Adipogen (San Diego, CA) and sheep
polyclonal anti-NLRP3 from R&D systems (Minneapolis, MN).
Monoclonal anti-GPSM3 antibody was produced by the UNC
Antibody Core Facility and has been previously described (20).
All cDNAs used in this report were cloned in the pcDNA3.1
backbone vector (Invitrogen, Carlsbad, CA), with Flag- or HA-
epitope tag sequences included in the forward PCR primer to
produce N-terminal-tagged open-reading frames as described
previously (20). Recombinant Staphylococcus aureus  hemol-
ysin was generated as previously described (21). Aluminum
hydroxide suspension (Imject Alum) was purchased from
Thermo Scientific.
Cell Culture and Transfection—Human embryonic kidney
293 (HEK293) and THP-1 cell lines were each obtained from
the American Type Culture Collection (ATCC) and main-
tained in DMEM or RPMI 1640 media (Invitrogen), respec-
tively, supplemented with 10% fetal bovine serum (Cellgro,
Manassas, VA) at 37 °C in a humidified atmosphere containing
5% CO2. Transient transfections of cell monolayers grown to
75–90% confluence were performed using Lipofectamine 2000
(Invitrogen) according to the manufacturer’s instructions.
Immunoprecipitation and Immunoblotting—Cells were lysed
with ice-cold lysis buffer (20 mM HEPES, pH 7.5, 1 mM EDTA,
150 mM NaCl, 1% Nonidet P-40, and Complete protease inhib-
itor mixture tablets (Roche, Indianapolis, IN)) at 4 °C on a
rocker platform for 30 min. Lysates were clarified by centrifu-
gation at 16,000  g for 15 min at 4 °C and quantified by the
bicinchoninic acid (BCA) protein content assay (Pierce). For
immunoprecipitation, lysates were incubated with specific
antibody for 2 h at 4 °C followed by overnight incubation with
protein-A/G agarose (Santa Cruz Biotechnology), or directly
incubated with agarose-conjugated anti-Flag M2 antibody over-
night. Pelleted antibody/bead complexes were then washed three
times with lysis buffer and proteins eluted in Laemmli buffer.
Eluted proteins or lysate samples were resolved on 4–12% precast
SDS-polyacrylamide gels (Novex/Invitrogen), transferred to nitro-
cellulose, immunoblotted using primary and HRP-conjugated sec-
ondary antibodies, and visualized by chemiluminescence (ECL,
GE Healthcare).
Bioluminescence Resonance Energy Transfer (BRET)—HEK293
cells were seeded in 12-well plates (3.5  105 cells/well) and
transfected with fixed amount of RLuc-GPSM3 or RLuc-
GPSM3 LSL mutant vector DNA (50 ng) and increasing
amounts of GFP10-NLRP3 vector DNA (0 –1500 ng) and cor-
responding (decreasing) amounts of pcDNA3 empty vector
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(1500 to 0 ng) to obtain a saturation curve. The others BRET
assays were performed by transfecting cells with 50 ng of the
RLuc fusion protein-expressing vector with 750 ng of GFP10
fusion protein expressing vector as indicated. 24 h post-trans-
fection, cells were washed once, harvested, and resuspended in
BRET buffer (phosphate-buffered saline with 1 mM CaCl2, 0.5
mM MgCl2, 0.1% glucose) and distributed in white 96-well
microplates. BRET was initiated by adding coelenterazine-400a
at a final concentration of 5 M. Measurements of emitted light
were collected on a Mithras LB-940 plate-reader (Berthold
Technologies) using a BRET2 filter set.
Bimolecular Fluorescence Complementation (BiFC)—Fusion
constructs were made similar to those previously described
(19): namely, a fusion of the N-terminal fragment (aa 1–158) of
yellow fluorescent protein (YN) to the N terminus of full-length
GPSM3 (“YN-GPSM3”) and the C-terminal fragment (aa 159 –
238) of YFP (YC) to the C terminus of NLRP3 (“NLRP3-YC”).
HEK293 cells were transfected with an equal amount of
plasmids encoding the fusion proteins YN-GPSM3 and
NLRP3-YC, and cells were incubated at 37 °C for 24 h. Total
DNA quantity was normalized using empty pcDNA3.1 vector
DNA. To measure fluorescence from formed complexes, trans-
fected cells were washed, harvested, and resuspended in PBS.
BiFC signal was acquired using a Mithras LB-940 plate-reader
using an excitation/emission filter set of 485 and 510 nm. The
level of expression of each fusion protein was quantified by
Western blotting using a polyclonal antibody directed against
the GFP.
Immunofluorescence Microscopy—HEK293 cells were seeded
in a 12-well plate and transfected with 0.4 g of each DNA:
YN-GPSM3 and NLRP3-YC. The following day, cells were
transferred to a poly-D-lysine (PDL)-coated coverslip in a 6-well
plate and grown overnight. Cells were then fixed with 4% para-
formaldehyde plus PBS for 10 min at room temperature. Cov-
erslips were mounted using Vectashield mounting medium
containing DAPI (Vector Laboratories, Burlingame, CA) and
examined by inverted epifluorescence microscopy (Olympus
IX70) using a 40 objective.
Mice—Gpsm3(/) mice were generated as previously
described (16). Nlrp3(/) mice were a kind gift from Dr. John
Bertin (Millennium Pharmaceuticals) and were further back-
crossed at UNC to achieve nine generations of backcrossing
onto the C57BL/6 background. Nlrc4(/) mice were pro-
duced using C57BL/6 embryonic stem (ES) cells and were a
kind gift from Dr. Vishva Dixit (Genentech) (23). Aim2(/)
mice were generated using C57BL/6 ES cells by inGenious Tar-
geting Laboratory (Ronkonkoma, NY).4
Bone Marrow-derived Macrophages (BMDMs) Isolation and
Culture—BMDMs were prepared from 9 –12-week-old mice.
Briefly, femurs and tibiae were removed from CO2 euthanized
mice. Both ends of the bones were cut and bone marrow cells
were extracted by flushing with DMEM medium containing
10% FBS using a syringe with a 27-gauge needle. Cell suspen-
sion was filtered through a 75-m cell strainer and then centri-
fuged and resuspended in RBC lysis buffer (150 mM NH4Cl, 10
mM KCO3, 0.1 mM EDTA, pH 7.4) for 10 min on ice. Cells were
washed in complete medium and finally resuspended at a den-
sity of 4  106 cells/ml in macrophage-conditioned medium
(DMEM containing 10% FBS and 20% L-929 culture superna-
tant as source of M-CSF). Cells were seeded in 10-cm tissue
culture plate (4  106 cells/plate) in 10-ml final volume. Three
days later, 10 ml of fresh macrophage-conditioned medium was
added and replaced with 10 ml of fresh medium at day 6 and day
8. Cells were collected from culture dishes at day 8 by washing
once with PBS and treated with 5 ml of Accutase (Sigma) for 5
min at 37 °C.
Ex Vivo Inflammasome Activation Assay—BMDMs were
resuspended in serum-free RPMI 1640 and seeded in a 24-well
plate at a density of 1  106 cells/ml/well. LPS (100 ng/ml) was
added for 3 h. Subsequently, cells were stimulated with
NLRP3’s inflammasome activators as indicated: ATP (5 mM), 
hemolysin (10 g/ml), and aluminum hydroxide (130 g/ml
ImjectTM, Pierce) for 1 h. For AIM2 inflammasome activation,
dsDNA (2 g/ml, poly(dA:dT)/LyovecTM, Invivogen) was used
and cells treated for 15 h. For NLRC4 inflammasome activation,
LPS treated macrophages were then transduced with 250 ng/ml
flagellin (Invivogen) using Profect-P2 (1.25 l/ml, Targeting
Systems) as described by Miao et al. (24) for 1 h. Culture super-
natants were collected after centrifugation at 13,000  g for 10
min, and cytokines (IL-1 and TNF) were measured by
enzyme-linked immunosorbent assay (ELISA) as described by
Craven et al. (21).
Quantitative RT-PCR—THP-1 or bone marrow-derived
macrophage (BMDM) cells were activated as previously
described with LPS (100 ng/ml) and/or -hemolysin (10 g/ml).
Cells were harvested and lysed in buffer RLT (Qiagen)  1%
2-mercaptoethanol (Fisher) before immediately being placed
on ice. RNA extraction was performed using the Qiagen
RNeasy kit following the manufacturer’s instructions, and iso-
lated RNA was DNase-I treated and used to synthesize cDNA
immediately (Thermo Verso cDNA synthesis kit). Relative gene
expression was quantified using Veriquest Fast Probe PCR master
mix (Affymetrix) and Taqman probes (Invitrogen) for GPSM3,
NLPR3, and IL1B normalized to multiplexed 2-microglobin.
Fold change in target gene expression was calculated using thresh-
old values by the 2Ct method, described by Livak and Schmit-
tgen (25), and statistical significance was determined by one-way
ANOVA with Bonferroni post-hoc (p  0.05).
In Vivo Peritonitis Experiments—Gpsm3(/), Nlrp3(/),
and wild type littermate control mice were first pretreated
intraperitoneally (intraperitoneal) with LPS (20 mg/kg) and
subsequently injected 2 h later with 350 g Alum (Pierce), an
NLRP3-dependent inflammasome activator (26). Peritoneal
exudate and peripheral blood were both collected and perito-
neal cavity rinses with 3 ml of PBS (intraperitoneal lavage) and
both samples mixed together and cytokine content quantified
as described previously for the ex vivo assay. Cardiac puncture
was used to bleed mice. Serum was collected from coagulated
blood that had been centrifuged.
4 J. E. Wilson, A. S. Petrucelli, L. Chen, A. A. Koblansky, Y. Oyama, A. D. Truax, M.
Schneider, A. B. Rogers, M. Mühlbauer, B. R. Barker, W.-C. Chou, W. J.
Brickey, I. C. Allen, C. Jobin, D. Ramsden, B. K. Davis, and J. P. Ting, manu-
script in preparation.
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RESULTS
GPSM3 Interacts with the C-terminal End of NLRP3—Yeast
two-hybrid screening for potential GPSM3-associated proteins
within a commercial, 106 clone human leukocyte cDNA
library identified NLRP3, a critical component of the mono-
cyte inflammasome complex, as a potential GPSM3-interact-
ing protein. Fig. 1A shows the growth under auxotrophic selec-
tion of yeast transfected with the cDNA encoding full-length
GPSM3 fused to the Gal4 DNA binding domain (bait) and the
NLRP3-transcriptional activation domain fusion encoding the
partial NLRP3 clone initially retrieved in the screen (prey).
Sequence analysis of this prey clone revealed the last four
leucine-rich repeats of NLRP3 (aa 831–979) in frame with
the Gal4-transcriptional activation domain (Fig. 1B). To fur-
ther characterize this interaction, cDNA encoding HA
epitope-tagged NLRP3 and FLAG epitope-tagged GPSM3 were
co-transfected in HEK293 cells which do not express either
protein endogenously. Full-length NLRP3, as well as its C-ter-
minal fragment (aa 831–979), were each efficiently co-immu-
noprecipitated with GPSM3 using anti-Flag antibodies (Fig. 1,
C and D, respectively).
Our group has previously described different point muta-
tions to GPSM3 that abolish specific interactions with its
known heterotrimeric G protein binding partners: GiGDP
and monomeric G subunits. For example, mutation to phenyl-
alanine of two arginines at positions 81 and 152, within the
critical triad sequences of the first and third GoLoco motifs,
completely abolishes direct interaction with GiGDP subunits
(herein described as the RF mutant) (19) (Fig. 1B). Moreover,
the point mutations 58LSL60-to-PLP, within a leucine-rich
motif upstream of the first GoLoco motif, dramatically reduce
the association of GPSM3 with monomeric G subunits





pGAD424 NLRP3 pGAD424 NLRP3
A
B
IP: Flag    IB: Flag
Lysate    IB: HA
IP: Flag     IB: HA
14kDa98kDa
IP: Flag     IB: HA
IP: Flag    IB: Flag












+ +++NLRP3-HA - + +++





















FIGURE 1. Identification of NLRP3 as a GPSM3-interacting protein. A, Saccharomyces cerevisiae were co-transformed with indicated bait plasmids (either
expressing the Gal4p DNA binding domain alone [pAS2-1] or as a fusion with full-length GPSM3 [pAS2-1/GPSM3]) and prey plasmids (either expressing the
Gal4p activation domain alone [pGAD424] or as a fusion with the C terminus of NLRP3 [pACT2/NLRP3]). Transformed yeast were plated onto synthetic defined
agar (Yc) lacking leucine (Leu, to select for the prey plasmid) and tryptophan (Trp, to select for the bait plasmid); growth on Yc LeuTrp medium
demonstrates incorporation of both bait and prey plasmids (left panel). Growth on Yc LeuTrp medium also deficient in adenine (Ade) and histidine (His)
indicates a positive protein-protein interaction (right panel). B, domain architecture of NLRP3 comprising the pyrin domain, nucleotide-binding domain (NBD),
and eight leucine-rich repeats (LRRs) in comparison to the truncated domain structure for the NLRP3 fragment identified in the yeast two-hybrid screen.
Additionally represented is the domain structure of GPSM3 comprising the three GoLoco motifs (GL1-GL3) and locations of point mutations used in this study.
Amino acid numbering for each domain is based on data from UniProt identifier Q96P20 (NLRP3) and Q9Y4H4 (GPSM3). C and D, HEK293 cells were transiently
co-transfected with plasmids expressing HA-tagged full-length NLRP3 (aa 1–979; panel C) or an NLRP3 C-terminal fragment (aa 831–979; panel D), along with
Flag-tagged GPSM3, either of wild type sequence (WT), R81F  R152F double mutant (RF; abrogates GPSM3/GiGDP interaction) or the LSL mutant in which
the GPSM3 amino acids 58LSL were mutated to PLP to eliminate the GPSM3/G interaction as previously described. Immunoprecipitation (IP) of GPSM3 was
performed using agarose-conjugated anti-Flag M2 antibody and co-immunoprecipitating proteins were detected by immunoblotting (IB) with anti-HA
epitope tag antibody. E, whole cell lysates from THP-1 cells were immunoprecipitated with anti-NLRP3 goat polyclonal antibody or with protein-A/-G agarose
beads alone. GPSM3 was subsequently detected using an anti-GPSM3 mouse monoclonal antibody (clone 35.5.1) and NLRP3 was detected with anti-NLRP3
mouse monoclonal antibody. Results shown are representative of two independent experiments.
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(herein described as the LSL mutant) (19) (Fig. 1B). While the
RF mutation did not perturb co-immunoprecipitation between
GPSM3 and NLRP3, the LSL mutation decreased the ability of
GPSM3 to interact with full-length and truncated NLRP3
(831–979) suggesting a common interacting protein or shared
binding site (Fig. 1, C and D, last lane), in a fashion similar to
that observed for the GPSM3/G interaction (19). To demon-
strate that the GPSM3/NLRP3 association is not an artifact of
protein overexpression, co-immunoprecipitation of endogenous
NLRP3 and GPSM3 was performed from the human monocytic
cell line, THP-1. A sheep polyclonal anti-NLRP3 antibody was
used to immunoprecipitate endogenous NLRP3 and associated
proteins. The immunoprecipitated complexes were analyzed for
the presence of GPSM3 using immunoblot with a mouse mono-
clonal anti-GPSM3 antibody (19, 20). Immunoprecipitation with
anti-NLRP3 antibodies led to capture of detectable endogenous
GPSM3 as well as NLRP3, while mock immunoprecipitation failed
to capture either protein (Fig. 1E).
Mapping the GPSM3 Interaction Site(s) within NLRP3—To
further characterize the GPSM3/NLRP3 interaction, biolumi-
nescence resonance energy transfer (BRET) was used to iden-
tify the minimal GPSM3 interaction domain within NLRP3.
Full-length GPSM3, fused to the luminescence donor Renilla
Luciferase (RLuc-GPSM3) was co-expressed with fusion pro-
teins comprising various domains of NLRP3 fused to the accep-
tor fluorescent protein GFP10 (GFP10-NLRP3, Fig. 2A). Any
interaction between RLuc-GPSM3 and the NLRP3 domain-
GFP10 fusion proteins brings the luciferase donor and GFP
acceptor proteins into close proximity, allowing energy trans-
fer. Cellular co-transfection with a fixed quantity of RLuc-
GPSM3 plasmid and a titration of increasing amounts of
GFP10-NLRP3 (full-length) plasmid generated a saturable sig-
nal (Fig. 2B) with a maximum net BRET ratio of 0.3. Further-
more, when the RLuc-GPSM3 fusion contained the LSL muta-
tion, the BRET signal with GFP10-NLRP3 was lost (Fig. 2B). Fig.
2C summarizes BRET experiment results between RLuc-
GPSM3 and a variety of GFP10-NLRP3 truncation constructs
(Fig. 2A). Expression of RLuc-GPSM3 with GFP10 fusion pro-
tein encoding solely the Pyrin domain of NLRP3 (Fig. 2C) gave
no observable BRET signal. Truncation of individual leucine-
rich repeat (LRR) domains, starting from the C terminus,
revealed the importance of the last LRR (aa 911–932) to the
GPSM3/NLRP3 interaction, as 50% of the signal was lost fol-
lowing its removal. However, a GFP10 fusion protein encoding
both the pyrin and NBD domains (GFP10-NLRP3 536 stop)
also produced 50% of the total netBRET signal (Fig. 2C).
This BRET-based evidence of interaction with the N-termi-
nal region of NLRP3 was surprising, given that the cDNA clone
retrieved from the yeast two-hybrid screen contained only the
last 4 LRRs of NLRP3 and interaction between GPSM3 and this
C-terminal NLRP3 fragment was confirmed by reciprocal co-
immunoprecipitation (Fig. 1). One possible explanation for also
detecting a GPSM3 interaction with the NLRP3 N-terminal
region is that the NBD domain is known to interact with the
C-terminal LRR portion, forming an intramolecular hairpin-
like structure (27). It is thus possible that, within the cellular
context, the NBD domain of NLRP3 interacts with endogenous
NLR proteins that might also interact with GPSM3. To deter-
mine whether GPSM3 could interact with the NLRP3 C termi-
nus without bridging by the NLRP3-NBD domain, we made a
GFP10 fusion construct expressing only the C-terminal LRRs of
NLRP3 (GFP10-NLRP3-LRR). Additionally, a truncation of the
GFP10-NLRP3-LRR fusion lacking the last LRR (aa 911–932)
was generated. As expected, the construct containing all the
C-terminal LRRs (i.e. NLRP3 without its pyrin and NBD
domains) was sufficient to generate a robust BRET signal (Fig.
2D). Removal of the final LRR abolished the BRET signal, con-
firming that the last LRR is required for interaction with
GPSM3. Removal of the residual C-terminal extension beyond
the final LRR domain (i.e. “NLRP3 934 stop”) had no effect on
the GPSM3/NLRP3 interaction as measured by BRET (Fig. 2D).
The interaction between GPSM3 and the GFP10-NLRP3-LRR
fusion protein was also confirmed by co-immunoprecipitation.
As also observed in the BRET assay, the co-immunoprecipita-
tion of GPSM3 and the GFP10-NLRP3-LRR fusion protein was
disrupted by deletion of the last LRR domain, but not the resid-
ual C-terminal amino acids (Fig. 3).
Subcellular Localization of the GPSM3/NLRP3 Interaction—
We employed a third protein-protein interaction assay, BiFC,
to confirm the interaction between GPSM3 and NLRP3 as well
as to study the localization of their complex, using previously
described methods (19, 20). The N-terminal portion of the yel-
low fluorescent protein (YFP) was fused to full-length GPSM3
(“YN-GPSM3”) and the C-terminal part of YFP was fused to
full-length NLRP3. When expressed alone or with the non-
fused counterpart, no detectable fluorescence was measured.
However, when both fusion proteins were expressed together
(YN-GPSM3  NLRP3-YC), a fluorescent signal was detectable
in transfected cells (Fig. 4). As further confirmation of the co-
immunoprecipitation and BRET results (Figs. 2 and 3), the LSL
mutation in GPSM3 greatly reduced the BiFC signal (Fig. 4A).
The YN-GPSM3/NLRP3-YC complex was seen to form punc-
tate structures throughout transfected cells as observed by fluo-
rescence microscopy (Fig. 4B). Ectopic expression of the
GFP10-NLRP3 fusion, which is inherently fluorescent without
binding the GPSM3 partner, was also observed to form similar
punctate structures, suggesting that the GPSM3 interaction
does not trigger this subcellular localization phenomenon nor
perturb the localization of overexpressed NLRP3 (Fig. 4B).
These large dots are likely oligomers of NLRP3, similar to those
observed by others using immunofluorescence-based studies of
either overexpressed NLRP3 or activation of native NLRP3 in
NLRP3-expressing cells (28 –30).
Functional Effects of the GPSM3/NLRP3 Interaction on
NLRP3-dependent IL-1 Secretion—To test the hypothesis
that the GPSM3 interaction regulates NLRP3 function and
inflammasome activation, bone marrow-derived macrophages
(BMDMs) were generated from GPSM3-deficient mice (16)
and IL-1 secretion quantified following inflammasome activa-
tion. Inflammasome-dependent IL-1 production requires ini-
tial priming using lipopolysaccharide (LPS) to induce pro-IL-
synthesis (31, 32). Following LPS stimulation, different inflam-
masome activators were added, and mature IL-1 secreted in
the medium was quantified. Activators of the NLRP3-depen-
dent inflammasome including ATP, -hemolysin (HLA), and
Alum induced robust IL-1 secretion with a significant
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FIGURE 2. Characterization of the GPSM3/NLRP3 interaction using BRET. A, domain architecture of full-length and truncated GFP10-NLRP3 fusion con-
structs used to characterize the GPSM3/NLRP3 interaction. B, constant amount of wild type (or LSL mutant) RLuc-GPSM3 fusion expression vector was
co-transfected into HEK293 cells with increasing amounts of GFP10-NLRP3 fusion expression vector; the resultant net BRET ratio was plotted as a function of
the acceptor/donor ratio. C, C-terminal truncation mutants were used to identify the minimal determinants within NLRP3 required for the interaction with
GPSM3. A stop codon was inserted by mutagenesis after each domain of the GFP10-NLRP3 fusion construct (as indicated) and subsequently tested in the BRET
assay upon co-expression with RLuc-GPSM3. D, leucine-rich repeat domains were fused to GFP10 (called “GFP10-NLRP3 LRR”) and used in the same BRET
experiment.
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increase in Gpsm3(/) mice after 4 h of stimulation com-
pared with littermate control mice (Fig. 5, A–C, left panels). As
expected, NLRP3-deficient mice showed no observable IL-1
secretion (Fig. 5, A–C, left panels). Inflammasome activation is
known to trigger release of IL-1 but not that of cytokines not
dependent on caspase-1 activation (26). TNF- was also quan-
tified in the culture supernatants from these stimulated macro-
phages and found to be secreted to the same extent by all three
mouse genotypes (Fig. 5, A–C, right panels); these results sug-
gest that GPSM3 regulation of cytokine secretion is specific for
those dependent on NLRP3-mediated caspase-1 activation.
The specificity of GPSM3 for the NLRP3 inflammasome sig-
naling pathway was also tested using dsDNA stimulation, an
AIM2-inflammasome activator (33), and a flagellin-derived
peptide known to activate the NLRC4-inflammasome (34).
BMDMs isolated from AIM2-, NLRC4-, and NLRP3-deficient
mice were used as controls. At 18 h post-treatment, dsDNA was
found to induce a similar release of IL-1 secretion in BMDMs
from WT mice as compared with Gpsm3(/) mice. As
predicted, BMDMs from Aim2(/) mice failed to secrete
IL-1 upon dsDNA stimulation; interestingly, NLRP3-defi-
cient BMDMs were found to have increased IL-1 release com-
pared with BMDMs from WT control and Gpsm3(/) mice
(Fig. 5C). Similarly, BMDMs from Nlrc4(/) mice showed
a significant decrease in IL-1 secretion in response to
flagellin, as expected (34) (Fig. 5D). Importantly, GPSM3-
deficient and WT BMDMs responded equally to dsDNA and
flagellin as an inflammasome stimulator (Fig. 5, D and E),
suggesting that GPSM3 regulation of inflammasomes is lim-
ited to the NLRP3-inflammasome.
To explore the involvement of GPSM3 in NLRP3-dependent
inflammasome activation in a more physiological context, we
employed a model of Alum-induced peritonitis and quantified
resultant IL-1 production from peritoneal lavage and blood
serum. Gpsm3(/), Nlrp3(/), and wild type littermate
control mice were first pretreated intraperitoneally (intraperito-
neal) with LPS and subsequently injected two hours later with
Alum, an NLRP3-dependent inflammasome activator (26). Perito-
neal exudate and peripheral blood were both collected and cyto-
kine content quantified. We observed that mature IL-1 secretion
was higher in both the lavage and serum of Alum-treated
Gpsm3(/) mice compared with WT controls, whereas blunted
IL-1 secretion was observed from Nlrp3(/) mice (Fig. 5F).
To explore the potential mechanism by which GPSM3 regu-
lates NLRP3-dependent IL-1 secretion, we undertook studies
of Nlrp3, Il1b, and Gpsm3 expression in primary mouse macro-
phages and the THP1 human monocytic cell line. WT and
Gpsm3(/) macrophages exhibited equivalent induction of
Nlrp3 and Il1b mRNA after treatment with LPS and/or -he-
molysin (Fig. 6, A and B), further suggesting that GPSM3 alters
IL-1 secretion through post-transcriptional regulation of
NLRP3. In THP1 cells, priming with LPS increased pro-IL-1-
encoding mRNA and decreased GPSM3 mRNA expression
(Fig. 6, C–E). GPSM3 protein levels were also found to be
decreased after treatment with LPS (Fig. 6F), suggesting that
priming by LPS relieves GPSM3-mediated inflammasome inhi-
bition in part through GPSM3 protein down-regulation.
The GPSM3/NLRP3 Complex Includes HSPA8 and Is Inde-
pendent of the GPSM3/1433 Interaction—The chaperonin
proteins HSP90, SGT1 (35–37), and HSP70 (38, 39) are known
to be essential in regulating NLRP3-inflammasome activation
(reviewed in Ref. 40). Cellular heat shock diminishes NLRP3-
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FIGURE 3. Co-immunoprecipitation of GFP10-NLRP3 protein constructs
with GPSM3. Flag-tagged GPSM3 was co-transfected with the same GFP10-
NLRP3 fusion proteins used to map the interaction by BRET (Fig. 2) and immu-
noprecipitation was performed using anti-Flag M2 agarose-conjugated anti-
body; co-immunoprecipitated proteins were detected by immunoblotting






















































FIGURE 4. Analysis of the GPSM3/NLRP3 interaction using BiFC. A, HEK293
cells were transfected with plasmids expressing YN-GPSM3 (aa 1–158 of YFP
fused to GPSM3) and NLRP3-YC (NLRP3 fused to aa 159 –238 of YFP) and the
fluorescence of reconstituted YFP fluorophore was measured at 24 h post-
transfection. Cells were harvested and fluorescence quantified on a plate
reader. Total DNA used for transfection was normalized using empty
pcDNA3.1 vector DNA. Data are expressed as relative fluorescence units (RFU)
using the means  S.E. of at least three different experiments; *, p  0.05; **,
p  0.01; and ***, p  0.001 by one-way ANOVA. B, epifluorescence micros-
copy images of HEK293 cells transfected with plasmids expressing the two
YFP protein fusions YN-GPSM3 and NLRP3-YC (top panel) or the GFP10-NLRP3
alone (bottom panel).
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these chaperonins are part of an inactive, basal-state NLRP3-
containing complex (41). The scaffolding protein RACK1
(“receptor for activated C kinases 1”), is required for the func-
tioning of a HSP90-, SGT1-, and HSP70-containing chaperonin
complex in rice which regulates innate immune signaling
through nucleotide binding leucine-rich repeat (NB-LRR)-type
R proteins (the rice orthologs of mammalian NLR proteins) and
other innate immune signaling systems (37, 42, 43). Our yeast
two-hybrid screen identified the heat shock protein HSPA8
(also known as HSC70 or HSP73) and RACK1 as additional
GPSM3-interacting proteins, suggesting that GPSM3 may
be involved in chaperonin-mediated regulation of NLRP3
function. We thus co-expressed Flag-tagged GPSM3 and HA-
tagged NLRP3 in the presence or absence of HA-HSPA8 and
HA-RACK1 for co-immunoprecipitation analyses. Immuno-
precipitation of GPSM3 revealed formation of a complex com-
prising GPSM3, NLRP3, and HSPA8 but excluding RACK1
(Fig. 7A). Co-expression of HSPA8 increased complex forma-
tion between GPSM3 and NLRP3; surprisingly, co-expression
of RACK1 also increased GPSM3-NLRP3 complex formation,
and co-expression of RACK1 and HSPA8 was found to act syn-
ergistically on complex formation. The LSL mutant of GPSM3,
previously found to have a greatly reduced interaction with
NLRP3 (Fig. 1), also failed to interact with HSPA8 (Fig. 7, A and
B, lane 7), suggesting a common binding site or partner. In addi-
tion, overexpression of RACK1 and HSPA8 was found to increase
fluorescence signal between YN-GPSM3 and NLRP3-YC as
observed using the BiFC assay (Fig. 7B). This result supports the
idea of a synergistic effect of RACK1 and HSPA8 on GPSM3-
NLRP3 complex formation.
We recently described GPSM3 as interacting directly with
the adaptor protein 14-3-3 (20). Given that numerous heat
FIGURE 5. GPSM3 deficiency leads to selective enhancement of the activation of the NLRP3-dependent inflammasome in macrophages ex vivo and in
a mouse NLRP3-dependent peritonitis in vivo. BMDMs were generated from wild type (WT), Gpsm3(/) and Nlrp3(/) mice (panels A, B, and C), or with
WT, Gpsm3(/), Nlrp3(/), Nlrc4(/), and Aim2(/) mice (panels D and E), and primed with LPS for indicated times at 50 ng/ml before treatment with
specific NLR inducers. ATP at 1 mM, S. aureus HLA at 10 g/ml and aluminum hydroxide and potassium salts (Alum) at 130 g/ml were used to activate the
NLRP3-inflammasome. Mouse macrophages were also separately transfected with dsDNA to activate AIM2 or flagellin peptide to activate NLRC4, as described
under “Materials and Methods.” Cell culture supernatant was collected following treatment and secreted IL-1 and TNF- quantified by ELISA as indicated. F,
12-weeks old, wild type littermate (WT), Gpsm3(/), and Nlrp3(/) mice were each initially primed by an intraperitoneal injection of LPS (20 mg/kg) and
subsequently injected 2 h later with 350 g of Alum (or saline vehicle, as indicated). Peritoneal exudate was collected and the peritoneal cavity rinsed with 3
ml of PBS (“intraperitoneal lavage”) and IL-1 content quantified by ELISA (right panel). Peripheral blood was also collected, and serum IL-1 was quantified by
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FIGURE 6. Pro-IL-1 and GPSM3 are reciprocally regulated during LPS-induced inflammasome priming. BMDMs were generated from WT or
Gpsm3(/) mice and primed with LPS for 3 h with 100 ng/ml and/or subsequently treated with HLA for 1 h, as indicated. Il1b and Nlrp3 mRNA levels in each
cell line were assessed using quantitative RT-PCR as described under “Materials and Methods” (panels A and B). THP1 cells were treated with LPS (100 ng/ml) or
vehicle for 3 h. GPSM3, IL1B, and NLRP3 mRNA levels were assessed by quantitative RT-PCR (panels C, D, and E). Data are expressed relative to the 2 M gene
transcript; *, p  0.05 by one-way ANOVA. GPSM3 and actin (loading control) protein levels were also assessed using immunoblot analysis with the indicated
antibodies (panel F). Samples from three independent experiments are shown.
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shock proteins are known to interact or form a complex with
14-3-3 proteins, including HSPA8 (44), we tested whether
14-3-3 proteins were involved in complex formation between
GPSM3, HSPA8, and NLRP3. As previously described (20),
mutation of a critical serine 35 within the 14-3-3-binding site of
GPSM3 abolishes interaction with 14-3-3. However, the GPSM3
S35A mutant was seen to associate with HSPA8 and NLRP3 iden-
tically as wild-type GPSM3 (Fig. 7C), while completely abolishing
the 14-3-3 interaction, as previously reported (20).
DISCUSSION
Activation of NLRP3 by various danger signals contributes to
pathologic inflammatory responses that drive a number of
disease states (12). Presumably the capacity to generate
potent pathologic inflammatory responses has led to the
evolution of a multistage activation process to rein in NLRP3
inflammasome activity to minimize inappropriate inflamma-
tion-driven pathologies. An unbiased screen for proteins that
interact with the protein GPSM3 identified a potential interac-
tion with NLRP3. Our present results support an endogenous
and physiologic interaction between NLRP3 and GPSM3, and
the notion that GPSM3 exerts a negative regulatory effect on
the function of NLRP3. Interestingly, GPSM3 has been found to
contribute to the induction of acute inflammation in a collagen
antibody-induced arthritis mouse model of acute inflammatory
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FIGURE 7. The heat shock protein HSPA8 is involved in the interaction between NLRP3 and GPSM3. A, to assess potential roles of HSPA8 and RACK1 in the
interaction between NLRP3 and GPSM3, HEK293 cells were transiently co-transfected with plasmids encoding Flag-tagged GPSM3, HA-tagged NLRP3, HA-
tagged HSPA8, and/or C-terminal HA-tagged RACK1. Immunoprecipitation (IP) of GPSM3 performed using agarose-conjugate anti-Flag M2 antibody revealed
the presence of HSPA8 in the complex, but the absence of RACK1, when immunoblotted with anti-HA. B, HEK293 cells were transfected with plasmids
expressing YN-GPSM3 and NLRP3-YC in the presence or absence of RACK1 and HSPA8 and the fluorescence of reconstituted YFP fluorophore was measured
at 24 h post-transfection. Cells were harvested and fluorescence quantified on a plate reader. Total DNA used for transfection was normalized using empty
pcDNA3.1 vector DNA. Data are expressed as relative fluorescence units (RFU) using the means  S.E. of at least three different experiments; *, p  0.05; **, p 
0.01; and ***, p  0.001 by one-way ANOVA. C, to assess the role of the known GPSM3 interactor 14-3-3, HEK293 cells were similarly co-transfected with
Flag-tagged wild type GPSM3 or GPSM3 R35A mutant (a loss-of-function mutant abolishing interaction with 14-3-3; Ref. 20) and HA-tagged HSPA8 and
HA-tagged 14-3-3.
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ated by the influence of GPSM3 on monocyte apoptosis and
chemotaxis in response to several G protein-coupled receptor
activating chemokines (16). This proinflammatory role of
GPSM3 does not contradict the negative regulation of the
NLRP3 inflammasome that we now describe because induction
of collagen antibody-induced arthritis has previously been
shown as independent of NLRP3 inflammasome activation (45,
46). Our current data suggest that GPSM3 has pleiotropic
effects on immune signaling pathways and that, in addition to
modulation of G protein-coupled receptor signaling, it is also
able to regulate NLRP3 inflammasome activation.
Using a combination of methodologies, we have shown that
GPSM3 interacts with the distal C-terminal region of NLRP3
and absolutely requires the last leucine-rich repeat domain
(LRR8). Because no structural information is yet available for
either protein, we cannot exclude other determinants within
NLRP3 that are also important for this association. The LRR
domains of NLR proteins are generally believed to serve as
ligand-binding domains for these innate immune sensors.
Although the structure of the LRR domain of NLRP3 has not yet
been elucidated, the LRR domains of NLR proteins are believed
to adopt a horseshoe tertiary structure akin to other LRR-con-
taining proteins. Crystal structures of the LRR portion of differ-
ent TLR receptors have been elucidated in the presence of dif-
ferent molecular ligands including dsRNA (47), LPS (48), and
lipoprotein (49), as well as the dsRNA-binding C terminus of
the NLR protein NLRX1 (50). It is possible that GPSM3 inter-
feres with the ability of NLRP3 to interact with activating
ligands through interaction with the final LRR domain of
NLRP3. A horseshoe tertiary structure for the LRR domains, if
also present within NLRP3, might allow intramolecular inter-
action of the C-terminal LRR domains with the N-terminal
NBD domain to facilitate the formation of a closed inactive
state, similarly to that described by the NLRC4 crystal structure
(51). The observed residual BRET signal between GPSM3 and
NLRP3 constructs lacking the LRR domains raises the possibil-
ity of an endogenous NLR protein bridging truncated (LRR-
lacking) NLRP3 mutants and GPSM3 (52). However, one could
FIGURE 8. Model of NLRP3 regulation by GPSM3. Formation of a network between GPSM3, chaperones, and NLRP3 maintains the steady-state level of NLRP3
by stabilizing it within this complex. Activation of the inflammasome requires two independent signals. Toll-like receptors (TLR) and tumor-necrosis factor
receptors (TNFR) are known to trigger priming signals leading to up-regulation of NLRP3 and pro-IL1 through a NFB-dependent pathway, as well as
down-regulation of GPSM3 mRNA and protein levels. Non-transcriptional priming of NLRP3 allows inflammasome activation upon detection of the activation
signal. The NLPR3 activation signal is triggered by endogenous DAMPs or exogenous PAMPs danger signals. Activation of NLRP3 can also be mediated by
bacterial pore-forming toxins such as the HLA of S. aureus. Activation of NLRP3 leads to formation of a multiprotein complex containing oligomerized NLRP3,
the adaptor ASC, and caspase-1. Once activated, caspase-1 cleaves pro-IL1 (and pro-IL-18), releasing the biological active form of IL-1 (and IL-18) and thereby
triggering inflammation and antimicrobial activity.
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also speculate that, if GPSM3 is capable of simultaneously
interacting with both the N terminus and the LRR domain of
NLRP3, such an interaction could inhibit release of the NLRP3
N terminus and LRR domain, thereby locking the protein in an
inactive form. Further experiments are clearly required to
determine if either one of these mechanisms is involved in the
inhibition of NLRP3 by GPSM3.
A two-step regulatory circuit for cellular IL-1 secretion, in
which pro-IL-1 is induced by TLR stimulation and NLRP3
inflammasome-mediated caspase-1 activation is induced by a
distinct second signaling event, has been a widely accepted
model (53). The first step, or “signal 1,” of regulation of inflam-
masome-mediated IL-1 secretion is a cell surface receptor-
induced NF-B transcriptional activation event that can be
initiated by various TLR-activating stimuli or by numerous
cytokine receptors. TLR stimulation primes cells for IL-1
secretion by enhancing pro-IL-1 production and by increas-
ing production of NLRP3, which is a very low abundance pro-
tein under basal conditions. Our data indicate that, as NLRP3
and IL1B are up-regulated, the negative regulator GPSM3 is
transcriptionally down-regulated as well. A heterogenous
group of stimuli then provide “signal 2,” leading to post-tran-
scriptional activation of NLRP3 (reviewed in Ref. 53). The acti-
vation of NLRP3 by “signal 2” is now known to further require a
post-transcriptional deubiquitination event that is catalyzed by
the DUB class of deubiquitinases (22). These data suggest that,
in its basal state, NLRP3 is ubiquitinated. A complex containing
HSP90 and the ubiquitin ligase subunit SGT1 is required for
NLRP3 signaling in mammalian cells, and these proteins may
be involved in the baseline ubiquitination of NLRP3 that has
been previously observed (40). We have now presented data
demonstrating that one other chaperonin protein, HSPA8, is
also found in complex with NLRP3 and GPSM3. These data
suggest the possibility of a third mechanism by which GPSM3
inhibits NLRP3 activation: namely, that GPSM3 may exert a
negative regulatory effect on NLRP3 by helping to bring the
latter protein to a basal heat shock protein ubiquitination/
chaperonin complex. Based on our present study and recent
advances in the field, we propose a revised model of basal
NLRP3 regulation (Fig. 8). The role of GPSM3 in promoting
NLRP3 inactivation and whether this negative regulatory path-
way can be exploited therapeutically in cases of pathologic
NLRP3 activation remain areas for further study.
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